Ryan Gentzler, MD· @ryangentzler · X·· 15 hours agoScore70
Body · original
Excited to see the highly anticipated DeLLphi-305 at #ESMO26. First line maintenance tarlatamab + durvalumab improves PFS and OS.
Updated label for outpt monitoring hopefully make this more accessible for all #SCLC patients.
The next frontier: Limited Stage consolidation
46 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Ryan Gentzler, MD · x.com